Clinical Effects of COPAXONE(R) or Interferon Therapy Compared to Untreated RRMS Patients
The percentages of relapse-free patients in each group were: COPAXONE -- 83 percent; Avonex -- 65 percent; Rebif -- 60 percent; Betaseron -- 60 percent; no treatment -- 37 percent.
Adriana Carra, M.D., Department of Neurology, Hospital Britanico de Buenos Aires, Argentina, spoke about the results. "It is clear that immunomodulatory therapy is beneficial in the long-term treatment of relapsing-remitting patients compared to no treatment. Our data are similar to those observed in other studies published or presented."
Read it here.